The Medication Evidence Map.
What we know about anxiety medication, what we're still figuring out, and what the data can't tell us.
The medication evidence base for anxiety is wider and more nuanced than most coverage suggests. SSRIs and SNRIs are first-line for most adult anxiety disorders and the effect sizes are small to moderate, which means they work for a meaningful share of people but not everyone. Benzodiazepines work reliably in the short term, and the long-term picture is more complicated than either "they're fine" or "they're addictive" captures. Buspirone, hydroxyzine, pregabalin, and beta-blockers each have real evidence for specific use cases. The map below shows the published evidence by drug class and by use case so the reader can see where the data is strong, where it's narrow, and where the prescribing practice keeps outrunning the studies.
Evidence nodes
What the map shows
SSRIs are the broadest tool. Effect sizes are small to moderate across GAD, panic, social, and OCD (higher doses for OCD). SNRIs (venlafaxine, duloxetine) are similar in effect, sometimes preferred for comorbid pain or depression. Buspirone is GAD-specific and reliable for that narrow use, with a slow onset that suits chronic use rather than acute distress. Hydroxyzine has trial evidence for GAD and is non-controlled, which makes it useful when benzodiazepines aren't the right call. Pregabalin has the strongest non-benzodiazepine evidence for GAD outside the US (where it's more commonly prescribed for that indication). Benzodiazepines work, fast, and the discussion has to include tolerance, withdrawal, and cognitive effects, not just the question of dependence. Beta-blockers are performance-anxiety tools, not generalized anxiety tools. SSRI/SNRI discontinuation syndrome is real, predictable, and underdiscussed in patient handouts.
What the map doesn't show
- ·Most trials enroll patients without complicated medical or psychiatric comorbidity, and most prescribed patients have both. Real-world effect sizes are usually smaller than trial effect sizes.
- ·Long-term safety data for any of these drugs is better than coverage implies but never as good as anyone wants. Decades-long randomized data don't exist for any psychiatric medication.
- ·The benzodiazepine discussion is unusually polarized in coverage. The evidence is more "depends on patient, dose, duration, and concurrent meds" than either pole.
- ·Off-label prescribing is common and the trial evidence for off-label use is much thinner than the prescribing rates suggest.
- ·The discontinuation literature for SSRIs and SNRIs is improving but most patients aren't told what to expect.
Sources
How to cite this map
The Medication Evidence Map, AnxietyResearch.org. Built from SSRI and SNRI anxiety trial meta-analyses, the buspirone and hydroxyzine GAD trial literature, the pregabalin gabapentinoid anxiety literature, beta-blocker performance-anxiety studies, the benzodiazepine outcome literature, and the SSRI/SNRI discontinuation literature. Accessed [date]. https://anxietyresearch.org/evidence-maps/medication/
Your next step in The Shrink Network
You are here: AnxietyResearch, the evidence layer of The Shrink Network.
Each site in the network has one job. No matter where you enter, we help you find the next step that makes sense.
Get clinical care at shrinkMDWant to understand more first?